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ABSTRACT:
Bryostatin 1 is a naturally occurring complex macrolide with potent anti-neoplastic 
activity. However, its extremely low natural occurrence has impeded clinical 
advancement. We developed a strategy directed at the design of simplified and 
synthetically more accessible bryostatin analogs. Our lead analog, “picolog”, can 
be step-economically produced. Picolog, compared to bryostatin, exhibited superior 
growth inhibition of MYC-induced lymphoma in vitro. A key mechanism of picolog’s (and 
bryostatin’s) activity is activation of PKC. A novel nano-immunoassay (NIA) revealed 
that picolog treatment increased phospho-MEK2 in the PKC pathway.  Moreover, the 
inhibition of PKC abrogated picolog’s activity. Finally, picolog was highly potent at 
100 micrograms/kg and well tolerated at doses ranging from 100 micrograms/kg 
to 1 milligram/kg in vivo for the treatment of our aggressive model of MYC-induced 
lymphoma. We provide the first in vivo validation that the bryostatin analog, picolog, 
is a potential therapeutic agent for the treatment of cancer and other diseases. 
INTRODUCTION
Bryostatin 1 (Figure 1a), isolated from an 
extract of the marine bryozoan Bugula neritina, is the 
prototypical member of a family of complex macrolides 
that  has  garnered  significant  attention  from  chemists, 
biologists, and clinicians owing to its structural novelty 
and remarkable biological activities [1-4]. These 
activities include induction of apoptosis [2], reversal of 
multidrug resistance [2], immunogenic stimulation [5], 
enhancement of memory and cognition in animal models 
[6], postischemic neuronal rescue and synaptogenesis 
[7-8], and in vitro activation of latent HIV reservoirs [9-
10]. Thus far, bryostatin has been used in Phase I and II 
clinical trials against several types of cancers, both as a 
single agent and, more recently, in combination with 
other cancer chemotherapeutics [11-13]. It is also being 
evaluated in a recently opened trial for Alzheimer’s 
treatment (see http://clinicaltrials.gov). Remarkably, 
bryostatin 1 is so potent that only ~1 mg is needed for a 
16-week course of treatment of patients in cancer clinical 
trials [14]. The activity profile of bryostatin 1 makes it 
an excellent candidate for the treatment of a number of 
diseases that are considered the most significant global 
health challenges, including neurodegenerative disorders, 
HIV/AIDS, and cancer. 
Despite the enormous potential of bryostatin 1 
as a therapeutic agent, its clinical advancement and the 
search for even more effective derivatives have been 
hampered by its natural scarcity; a large scale GMP 
isolation, for example, provided only 18 grams of 
bryostatin from 14 tons of B. neritina [1]. Moreover, 
the natural product is difficult to modify as is needed to 
tune its selectivity toward targeting distinct molecular 
pathways and minimizing off-target toxicities. While 
significant progress has been made on alternative sources, 
aquaculture, engineered biosynthesis [15], and total 
synthesis [16-24] have not yet proven practical as a 
supply source. As a result, most preclinical and clinical 
work has been conducted with the dwindling supply of 
bryostatin 1 obtained in the original GMP isolation. A 
further complication arises from the low in vivo dosages of Oncotarget 2012; 3:  58 - 66 59 www.impactjournals.com/oncotarget
bryostatin and thus low plasma levels, which often prohibit 
traditional pathway and pharmacokinetic analyses owing 
to instrumental limits of detection [25]. The limited supply 
of bryostatin 1 and the absence of comparably potent and 
potentially more effective agents have slowed exploitation 
of this clinically promising lead. Given that bryostatin 
is neither evolved nor optimized for human therapeutic 
use, the design and synthesis of simplified and thus more 
synthetically accessible analogs that could exhibit superior 
clinical performance are goals of considerable immediate 
significance. Indeed, patient accrual in a recent clinical 
trial involving bryostatin was terminated early due, in 
part, to the potential of “more potent bryostatin analogs in 
development” [13].
Starting in the 1980s, the Wender group synthesized 
a number of bryostatin analogs that were designed for ease 
of synthesis and superior clinical performance [3, 26]. 
Significantly, several of these analogs display comparable 
or even superior activity when compared to bryostatin 1 
in in vitro models for both cancer and Alzheimer’s disease 
[4, 26-29]. One such analog, termed “picolog” (Figure 
1a), is a lead analog in the Wender library across all in 
vitro data sets and can be prepared in only 29 synthetic 
steps  in  quantities  sufficient  to  supply  preclinical 
studies and clinical trials [27]. Given the promising 
in vitro performance of this analog, evaluation of its in 
vivo performance is now a critical step for preclinical 
advancement. This current study marks the first in vivo 
investigation of this promising analog. 
We had several considerations in selecting a 
preclinical model for this initial in vivo administration of 
picolog. The natural product bryostatin 1, a modulator of 
protein kinase C (PKC) activity, has been shown to affect 
MYC regulation in leukemias and neuroblastomas [30-
33]; therefore, we chose to study the activity of picolog in 
a MYC-induced neoplasm. 
The Felsher laboratory has generated numerous 
conditional transgenic models of hematopoietic and 
epithelial malignancies that overexpress human c-MYC 
in  specific  tissue  compartments  [34-41].  Transgenic 
models have been invaluable for determining the role of 
MYC in tumor maintenance as well as for investigating 
potential efficacy of novel therapeutics against MYC-
induced cancer [34-42]. Furthermore, although bryostatin 
Figure 1. (a) Structures of bryostatin 1 and the structurally simplified (although comparably or more potent) analog “picolog.” (b) Picolog 
vs. bryostatin 1 dose response. Percentage of viable 4188 lymphoma cells is graphed (normalized to untreated controls) following 36 hour 
incubation with 1 nM, 10 nM, 100 nM, 1 μM, or 10 μM bryostatin 1 (green) or picolog (blue). Each bar represents the average of two 
values normalized to the average of two untreated control cell populations. P values (two-tailed unpaired t test): 0.664 (1 nM), 0.750 (10 
nM), 0.010 (100 nM), 0.096 (1 μM), 0.001 (10 μM). (c) Cell growth over time for untreated 4188 cells as well as those treated with picolog 
(50 nM, 100 nM, 250 nM, 500 nM) and doxycycline (200 ng/mL). Each point represents the average of two values. P values (72 hour time 
points, two-tailed unpaired t test compared to untreated): 0.054 (50 nM), 0.040 (100 nM), 0.022 (250 nM), 0.023 (500 nM), 0.018 (dox). 
(d) Cell growth (dotted lines) and death (solid lines) over time for untreated (red) 4188 cells as well as those treated with 200 nM picolog 
(green). Dead cells are defined as those staining positive for trypan blue, while living cells are defined as those excluding trypan blue. Each 
point represents the average of two values. P values (48 hour time points, two-tailed unpaired t test): 0.091 (living), 0.001 (dead).
O
O
O
OAc
O
O
O
O
OH
OH
OH
 
Bryostatin 1
26
19
1
CO2Me
MeO2C
H
7
13 HO
O
O
O O O
O
O
O
OH
OH
OH
26
19
1
CO2Me
H
7
13
Picolog
a 
a 
c  c     d 
b Oncotarget 2012; 3:  58 - 66 60 www.impactjournals.com/oncotarget
1 efficacy has been demonstrated in vitro and in vivo 
against a number of different neoplasms as both a single 
agent and as part of a combination regimen, 28% of all 
clinical trials involving bryostatin 1 have been for the 
treatment of lymphoma (see http://clinicaltrials.gov) 
[43-44]. Thus, to study the potential efficacy of picolog 
in an in vivo model with direct clinical implications, we 
selected the conditional transgenic model of a rapidly 
progressive lymphoma arising from MYC overexpression 
in the lymphoid compartment [34-41]. Using this model, 
we demonstrate for the first time that picolog administered 
in vivo is well tolerated and can inhibit the growth of 
aggressive, MYC-induced lymphoma.
RESULTS
Picolog is more potent than bryostatin 1 in vitro
The activity of picolog was compared to bryostatin 
1 in vitro. Concentrations ranging from 1 nM-10 μM 
were administered to a murine tumor-derived lymphoma 
cell line over 36 hours (Figure 1b). At all concentrations 
tested, picolog exhibited comparable or superior growth 
inhibition of lymphoma cells relative to bryostatin 1 (p < 
0.05 for 100 nM and 10 μM treatment groups). 
Over a 72 hour time period, cell growth curves of 
lymphoma cells treated with 50-500 nM picolog revealed 
a dose-dependent growth inhibition (Figure 1c). At the 
Figure 2. Cell growth and cell death over time for a panel of additional leukemia and lymphoma cell lines (Jurkat (T-cell leukemia), CA-46 
(Burkitt’s lymphoma), and 6780 (transgenic MYC-induced lymphoma)) treated with 100 nM picolog. 
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highest concentrations tested, (250 nM, 500 nM), picolog 
treatment was as effective at inhibiting cell growth as 
MYC inactivation with doxycycline. In addition to growth 
inhibition, a statistically significant (p < 0.05) increase 
in cell death was observed following treatment with 
200 nM picolog for 48 hours (Figure 1d). To determine 
if picolog inhibited growth of additional murine and 
human MYC-induced lymphoma cells, 100 nM picolog 
was administered to a panel of additional T- and B- cell 
lymphomas of human and murine origin (including human 
Jurkat T-cell lymphoma, CA-46 B-cell lymphoma, and 
6780 murine T-cell lymphoma, Figure 2). Picolog inhibits 
cell growth and induces cell death in a wide range of 
lymphomas and leukemias.
Picolog induces apoptosis through activation of 
PKC
We next sought to characterize the mechanism 
through which picolog exerts its activity. Bryostatin is 
known to induce apoptosis by activation of PKC effectors, 
but other targets have also been proposed [29]. To 
determine if picolog treatment induced apoptosis, annexin 
staining was performed. Following treatment with picolog 
for  48  hours,  significant  apoptosis,  but  not  cell  cycle 
arrest, was induced compared with untreated control (p 
= 0.002) (Figures 3a-c). Previously it was demonstrated 
that bryostatin can increase MEK phosphorylation via 
activation of the PKC pathway. Using a novel nanofluidic 
proteomic immunoassay (NIA) [45-46] that enabled 
highly quantitative detection of relative phosphorylation 
and protein expression, we examined if picolog could 
also  activate  PKC  and  induce  MEK  phosphorylation. 
NIA revealed two distinct phospho-isoforms of MEK2 
(Figure 3d). Prior to treatment, only 39% of MEK2 was 
in a phosphorylated state, with 61% of total MEK2 in the 
unphosphorylated state. Following treatment with picolog 
(100 nM) for 24 hours, relative MEK2 phosphorylation 
increased  to  70%.  Total  MEK2  phosphorylation 
(normalized to loading control) also increased (Figure 3e, 
p = 0.04). To determine if growth inhibitory activity of 
picolog was due to PKC activation, the broad spectrum 
PKC inhibitor Go6983 was administered alone or together 
with picolog (Figure 3f). PKC inhibition alone did not 
decrease cell growth. However, co-administration of 
Go6983 with picolog abrogated the activity of picolog, 
indicating that picolog induces apoptosis through 
activation of the PKC pathway. 
Figure 3. (a) Annexin-PE staining increased after treatment of 4188 cells with picolog (100 nM) for 48 hours (n=2). (b) Cell cycle analysis 
after 48 hours for untreated 4188 cells (n = 2) as well as cells treated with 100 nM picolog (n = 2). (c) Values for cell cycle analysis.  (d) 
NIA traces demonstrating relative ratios of phosphorylated and unphosphorylated isoforms of MEK2 in untreated 4188 cells (top) and 4188 
cells treated with picolog (100 nM, bottom). X-axis: Isoelectric point (pI). Y-axis: Relative Light Units (RLU). (e) NIA quantification of 
MEK2 phosphorylation, normalized to loading control (HSP70). Samples were analyzed in duplicate and graphed +/- SEM. (f) Cell growth 
over time for untreated 4188 cells as well as those treated with Go6983 (1 μM), picolog (100 nM), and picolog (100 nM) + Go6983 (1 μM). 
Each point represents the average of two values +/- SEM. P value (two-tailed unpaired t test): 0.042 (Pico (100 nM) + Go6983 (1 μM) vs. 
Pico (100 nM), 48 hour time points).
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Picolog inhibits tumor growth in vivo
Picolog’s therapeutic efficacy was investigated in 
vivo. Mice were injected subcutaneously with the 4188 
transgenic lymphoma-derived cell line. Cohorts of mice 
were treated with picolog (100 μg/kg, 500 μg/kg, 1 mg/
kg once daily, respectively) or doxycycline (to inhibit 
transgenic MYC via the Tet-system). None of the mice 
treated with picolog experienced any noticeable adverse 
side effects, including weight loss, immobility, or death. 
Upon histologic examination, no evidence of organ 
toxicity could be found in mice treated at the highest 
dose, 1 mg/kg (Figure 4a). Picolog was found to inhibit 
tumor growth in a reverse dose-dependent manner, with 
the 100 μg/kg dose eliciting the best response (Figure 4b). 
Statistically significant tumor growth inhibition (p < 0.05) 
was also observed for the 100 μg/kg treatment group. 
Overall, picolog was well tolerated and demonstrated 
promising therapeutic efficacy in vivo. 
DISCUSSION
Bryostatin 1 is a promising therapeutic lead that 
exhibits a unique portfolio of biological activities 
for the treatment of cancer and other diseases [1-4]. 
More recently, it has advanced to clinical trials for the 
treatment of cancer and of Alzheimer’s disease. Its further 
advancement is hampered however by its poor availability 
from natural sources. Its severely limited abundance, along 
with its complexity, has also limited access to comparably 
effective structural analogs, especially agents that might 
be tuned to minimize off-target clinical toxicities. We 
have used synthesis-informed design to create simplified 
bryostatin analogs that could supply clinical needs, 
especially if they exhibit the exceptional potency and 
thus low dose requirements of bryostatin 1. This current 
study was designed to determine whether a lead analog 
in this series is effective against in vivo models of cancer. 
We found that picolog, a synthetically available analog 
of bryostatin, has superior activity relative to the natural 
product bryostatin 1. In vitro, picolog is remarkably potent 
for inhibition of growth of MYC-induced lymphoma 
and leukemia cells, with activity seen at concentrations 
as low as 50 nM in vitro. Picolog induced apoptosis in 
vitro, a result that is consistent with a previous report 
using picolog to treat Toledo non-Hodgkin’s lymphoma 
cells [29]. Further, when dosing at 250 nM, the therapeutic 
efficacy of picolog was similar to targeted inhibition of 
the MYC oncogene. In mice treated with picolog in vivo, 
treatment with 100 µg/kg resulted in significant tumor 
growth inhibition. We have determined the optimal 
therapeutic dosing both in vitro and, for the first time, in 
Figure 4. (a) Histology sections stained with hematoxylin and eosin for tumor tissues and organs collected at time of necropsy. (b) Tumor 
growth over time for untreated mice (n = 3), mice treated with picolog (100 μg/kg n = 4, 500 μg/kg n = 4, 1 mg/kg n = 3) or doxycycline n 
= 4. *indicates statistical significance relative to PBS group (two-tailed unpaired t test: p = 0.005 (100 µg/kg, day 2), 0.04 (100 µg/kg, day 
4), and 0.03 (100 µg/kg, day 6)).
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vivo in a preclinical model of T-cell lymphoma. 
 Picolog’s promising therapeutic efficacy in vivo 
raises several points for discussion. Importantly, picolog 
was found to be well tolerated by mice at all dosages 
tested. Therapeutic  efficacy  using  as  little  as  100  μg/
kg suggests that picolog is highly potent, especially in 
comparison with standard chemotherapeutic agents that are 
typically administered in mice in the 1-500 mg/kg range. 
Interestingly, picolog inhibited tumor growth in a reverse 
dose-dependent manner. The reverse dose dependence 
observed is not unexpected as overstimulation of PKC 
at high concentrations could result in degradation or 
downregulation of the enzyme over time, a process which 
is also known to occur in a dose-dependent manner with 
bryostatin 1 and further underscores the similar activities 
of the two agents [47]. Continued in vivo investigation of 
picolog as well as other bryostatin analogs is warranted 
given the efficacy and tolerability that we observed. 
One mechanism of picolog’s activity is thought to 
involve the PKC pathway. Picolog is known to be a high 
affinity ligand for PKC (Ki = 0.25 nM) [27]. To measure 
activation of MEK in the PKC pathway we developed 
the use of a novel nano-immunoassay (NIA) that enabled 
highly quantitative detection of relative phosphorylation 
and protein expression. NIA revealed two distinct 
phospho-isoforms of MEK2 in the PKC pathway that 
were induced upon picolog treatment. Having the ability 
to make NIA proteomic measurements using nanoscale 
amounts of specimen as the drug goes through additional 
preclinical and future clinical studies would enable the 
development of novel clinical biomarkers for monitoring 
therapeutic efficacy. 
In our tumor model, we have determined that picolog 
induces PKC activation in rapidly dividing lymphoma 
cells. Other targets that activate this pathway, such as Ras, 
may also cooperate in the mechanism of tumor growth 
inhibition. Abrogation of activity by PKC inhibition 
is consistent with the pathways known to be directly 
modulated by bryostatin 1 and analogs [29]. Recent 
studies suggest that bryostatins also have the ability to 
activate the PKC pathway in normal lymphocytes [11, 13, 
48-50]. Thus, in addition to direct anti-neoplastic effects 
on tumor cells, picolog could also have anti-neoplastic 
effects on host immune cells. Further studies of therapeutic 
and immunotherapeutic activity of picolog across a range 
of tumors including hematologic and solid malignancies 
should be performed to further elucidate its mechanism 
of action.
While this study focused on picolog, it is noteworthy 
that over 100 other analogs have been produced in our 
series and more than 30 exhibit PKC potencies comparable 
to  or  better  than  bryostatin  1.  Significantly,  while 
exhibiting single digit nanomolar or picomolar potencies, 
selected members of this analog library exhibit differential 
PKC isoform selectivities, thus offering the potential 
for selective targeting and, consequently, therapeutic 
optimization [51]. Along with exciting clinical results 
involving bryostatin 1 in combination with other agents 
for the treatment of lymphoma [11, 13], our findings help 
to substantiate that additional B- and T-cell hematopoietic 
malignancies could be candidates for the continued in vivo 
investigation of picolog and bryostatin analogs that can be 
supplied and tuned for activity.
We have shown that the simplified bryostatin analog, 
picolog, which can be synthesized in quantities needed 
for clinical advancement, has superior in vitro activity to 
bryostatin 1 in inhibiting growth and inducing apoptosis in 
MYC-induced lymphoma. For the first time, we also have 
shown that this analog is effective in vivo in an animal 
model of cancer. When extrapolated to a clinical setting, 
dosages of picolog sufficient to treat patients could be 
readily supplied through synthesis. Therapeutic activity 
of picolog could be explored across a range of tumors 
including hematologic malignancies tested in this work, 
as well as a range of solid tumors known to have PKC 
dysregulation. Future efforts will focus on the continued 
preclinical investigation of bryostatin analogs, including 
further refinement of single agent in vivo activity as well 
as the examination of clinically relevant combination 
regimens and immunotherapeutic activity. 
MATERIALS AND METHODS
In Vitro Cell Growth and Cell Cycle Assays
Cell line growth conditions. Cell lines 4188 and 6780 
were derived by the Felsher Laboratory from transgenic 
mice conditionally over-expressing human c-MYC using 
the Tet-system [34-37, 39-41] and maintained between 
100,000 cells/mL and 2,000,000 cells/mL in RPMI 1640 
media (Gibco, 10% fetal bovine serum, 1% penicillin/
streptomycin added, 0.1% beta-mercaptoethanol added) in 
a 37 oC incubator (5% CO2). Jurkat cells (ATCC) and CA-
46 cells (ATCC) were maintained between 100,000 cells/
mL and 1,000,000 cells/mL in RPMI 1640 media (Gibco, 
10% fetal bovine serum, 1% penicillin/streptomycin 
added). Cell lines are routinely authenticated by flow 
cytometry phenotyping and gene expression studies. 
In vitro administration of picolog. In a 6-well 
plate (Costar, low evaporation lid), 4 mL cells in log-
growth phase (100,000-150,000 cells/mL) were added to 
each well. Next, agents (bryostatin 1, picolog, Go6983 
inhibitor) were added either as stock solutions in DMSO 
or as solutions in room temperature media (RPMI 1640) 
diluted from the DMSO stock solutions. Go6983 was 
purchased from Sigma Aldrich and diluted into DMSO 
stock solutions upon receipt. Each experimental group 
was dosed in duplicate, and untreated wells received 
DMSO in an equal concentration to the most concentrated 
treatment  group  (final  DMSO  concentration  <  0.1%). Oncotarget 2012; 3:  58 - 66 64 www.impactjournals.com/oncotarget
Doxycycline was added as a solution in 0.9% phosphate 
buffered saline. In the case of the PKC inhibitor (Go6983) 
combination dosing with picolog, picolog was dosed first 
followed immediately by the inhibitor. Cells were counted 
at 24-hour intervals using a hemocytometer and trypan 
blue staining. Values were obtained in duplicate for each 
control and treatment group. 
The data for these experiments was plotted using 
GraphPad Prism version 5.0 in an XY graph. Multiple 
hemocytometer counts for the same well were averaged. 
The data was plotted as the (number of living or dead 
cells)/10,000 over time. Points represented the average of 
the two duplicate values from each treatment group +/- the 
standard error of the mean. 
Cell cycle analysis. Cells were washed once with 
PBS, then resuspended in 70% EtOH/PBS for fixation 
and permeabilization, and stored at -20 oC. At the time of 
flow cytometry analysis, cells were washed once with PBS 
and resuspended in 20 μg/mL propidium iodide in PBS 
(Invitrogen). 10,000 events per sample were collected on a 
FacScan Flow Cytometer (BD Biosciences) and analyzed 
using CellQuest (BD Biosciences).
Apoptosis analysis. Cells were washed once with 
PBS, resuspended in 200 μL of 1X binding buffer (BD 
Pharmingen),  and  stained  with  20  μL Annexin  V-PE 
(BD  Pharmingen)/20  μL  7-AAD  (BD  Pharmingen). 
10,000 events per sample were collected on a FacScan 
Flow Cytometer (BD Biosciences) and analyzed using 
CellQuest (BD Biosciences).
Nanofluidic  Immunoassay  (NIA)  for 
Phosphoprotein Quantification
Samples were run in duplicate. Lysates for the 
isoelectric focusing experiments were generated by 
taking an aliquot of 100,000 cells from treatment wells 
in a 6-well plate (for the cell growth/death versus time 
experiments). In the case of the solid tumor tissue, 
lysates  were  generated  from  the  filtrate  of  the  tumor 
homogenization. Cells were lysed in 10 μL of MPER lysis 
buffer (Invitrogen) containing protease and phosphatase 
inhibitors (Invitrogen). After 30 minutes on ice, protein 
lysate was collected by centrifugation at 14,000 RPM 
at 4ο C for five minutes. For each sample well in the 96-
well plate, 12 μL pre-mix (1% standard (4.9, 7.0, 7.3) 
isoelectric point 2-11, ProteinSimple), 6 μL supernatant, 
and 6 μL HNTG were added. 50 μL/well of each primary 
antibody solution (1:100 MEK2 antibody (Cell Signaling), 
1:100 HSP70 antibody (Santa Cruz)) was diluted in 
antibody dilution buffer (ProteinSimple). 100 μL/well was 
added for each secondary antibody in another row on the 
96-well plate (1:500 dilution for anti rabbit-HRP (Santa 
Cruz), 1:250 dilution for anti mouse-HRP (Santa Cruz)). A 
96-well plate loaded with sample, primary, and secondary 
antibodies was placed into the Firefly 3000 instrument 
(previous platform generation to the current Nanopro1000,   
ProteinSimple). Compass software was used to set up and 
implement the run according to manufacturer protocols, 
to identify the peaks, quantitate the areas under the peaks, 
calculate the percent phosphorylation, and generate trace 
images. NIA best-fit traces are graphed showing isoelectric 
point (pI, x-axis) vs. relative light units (RLU, y-axis). 
Quantification  of  MEK2  phosphorylation  is  obtained 
by summing the area under the curve of phosphorylated 
peaks for each sample, then dividing the sum by the area 
under the curve for loading control (HSP70) in order to 
normalize for loading. Normalized MEK2 phosphorylation 
is graphed (RLU phospho-MEK2/ HSP70, y-axis) +/- 
SEM. 
In Vivo Study Using Picolog
Ten female FVBN mice were divided into treatment 
cohorts:  untreated,  doxycycline  (100  μg/ml)  control, 
picolog 100 μg/kg, picolog 500 μg/kg, and picolog 1 mg/
kg. Mice were housed and maintained in the Stanford 
University Research Animal Facility per approved 
APLAC protocols. On day zero, each mouse received 
bilateral subcutaneous flank injections of 800,000 4188 
cells per flank. Tumor size was monitored via caliper 
measurement and, on day six, treatment began. Mice from 
each group received 100 µL i.p. injections once daily. The 
untreated control mice received injections of 0.9% PBS 
with <0.1% DMSO. The doxycycline group received 
treatment in their drinking water. For the picolog treatment 
groups, a solid sample was dissolved in DMSO to make 
a 4 mM stock solution. This stock solution was diluted 
into 0.9% PBS, and mice received once daily 100 µL i.p. 
injections. Over the course of the study, tumor size was 
monitored via electronic caliper measurements. Mice were 
also weighed every 48 hours. Once tumor sizes reached ~ 
20 mm2, mice were sacrificed by asphyxiation with CO2 
gas. Immediately after sacrificing the mice, the brain, 
kidneys, liver, spleen, heart, and lungs were harvested 
along with the tumor tissue. The organs were fixed in 95% 
ethanol for future analysis. Solid tumor tissue was flash 
frozen in liquid nitrogen and stored at -80 oC. The solid 
frozen tumor tissue was used to generate lysates for the 
isoelectric focusing experiments. The tumor growth curves 
(tumor size represents tumor volume (calculation = length 
x width2 x 0.52)) were generated using GraphPad Prism 
version 5.0.
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